ArticleTherapeutic advances in gastroenterology2026
Metabolic syndrome and its individual components but not MASLD are associated with advanced fibrosis in primary biliary cholangitis.
Article in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The degree of coincidence and interaction between primary biliary cholangitis (PBC) on the one hand and metabolic syndrome (MetS) or metabolic dysfunction-associated steatotic liver disease (MASLD) on the other is unknown. Objectives: The aim of the study was to evaluate the associations between MASLD/MetS and PBC, with the focus on liver fibrosis (F). Design: Cross-sectional observational study. Methods: Cross-sectional observational study recruited consecutive patients treated for PBC prospectively from a single tertiary center. The control group was sampled, matched for age and sex, from the general population obtained from nation wide SIRIUS database, which aims to screen the general population for liver disease. Liver stiffness as a surrogate marker of liver fibrosis was the primary outcome, while achieving complete biochemical response (CBR) was a secondary outcome of our research. Results: Prevalence of MASLD was 42.3% in the PBC group and 41.9% in the control group (NS). Prevalence of MetS was 38.9% in PBC and 60.7% in the control group ( Conclusion: Patients with PBC appear to have a lower prevalence of MetS than age and sex matched general population, despite the same prevalence of MASLD in both groups. MetS but not MASLD was associated with the presence of advanced fibrosis in patients with PBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.